Keeping the blood flowing: New agents to prevent and treat thrombosis

D. Fitzmaurice

    Research output: Contribution to journalArticlepeer-review


    We live in exciting times with the development of several new oral anticoagulant agents, including the recent approval of the direct thrombin inhibitor dabigatran for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). Dabigatran, an oral agent with fixed dosing, is an attractive alternative to warfarin which has recently been made available in the UK. What are the implications for UK primary care? Many patients with AF receive substandard anticoagulation and are therefore at risk of stroke. Evidence for its efficacy and its potential place in clinical practice is reviewed.
    Original languageEnglish
    Pages (from-to)147-148
    Number of pages2
    JournalPrimary Care Cardiovascular Journal (PCCJ)
    Issue number4
    Publication statusPublished - 1 Oct 2011


    Dive into the research topics of 'Keeping the blood flowing: New agents to prevent and treat thrombosis'. Together they form a unique fingerprint.

    Cite this